Hilltop Holdings Inc. Trims Stake in Pfizer Inc. $PFE

Hilltop Holdings Inc. reduced its holdings in Pfizer Inc. (NYSE:PFE) by 27.5% during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 126,065 shares of the biopharmaceutical company’s stock after selling 47,883 shares during the quarter. Hilltop Holdings Inc.’s holdings in Pfizer were worth $3,540,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of the business. Godfrey Financial Associates Inc. purchased a new position in shares of Pfizer during the fourth quarter worth about $26,000. YANKCOM Partnership bought a new position in shares of Pfizer in the fourth quarter worth approximately $28,000. HFM Investment Advisors LLC raised its stake in Pfizer by 61.0% in the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 427 shares in the last quarter. Evolution Wealth Management Inc. raised its stake in Pfizer by 132.2% in the first quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 566 shares in the last quarter. Finally, Abound Financial LLC bought a new stake in Pfizer during the fourth quarter valued at approximately $31,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer announced that PF-08057418 cleared a Phase 1 safety milestone, which helps reinforce confidence in the company’s research pipeline and early-stage development prospects. Article: Pfizer’s PF-08057418 Clears Phase 1 Safety Milestone, Offering a Quiet Boost to Pipeline Confidence
• Positive Sentiment: Pfizer is advancing PF-08653945 into an early-stage obesity trial, giving investors another potential growth driver in a large and competitive therapeutic market. Article: Pfizer Advances New Obesity Shot With Early Stage Trial of PF-08653945
• Positive Sentiment: The FDA granted Priority Review to Pfizer’s Talzenna plus Xtandi regimen for metastatic prostate cancer, which improves the odds of a faster regulatory decision and supports oncology revenue upside if approved. Article: FDA Grants Priority Review for Pfizer’s TALZENNA Plus XTANDI for the Treatment of Metastatic Prostate Cancer
• Neutral Sentiment: Unusual call option activity suggests traders are positioning for a move in Pfizer shares, but it does not by itself confirm a fundamental change in the company’s outlook.
• Neutral Sentiment: Recent commentary on Pfizer’s dividend yield and oncology valuation highlights that investors are still weighing income appeal against execution and growth concerns.
• Negative Sentiment: Expanded patent litigation tied to Pfizer’s mRNA vaccine business remains a potential overhang, adding legal and operational uncertainty that could pressure sentiment if the dispute escalates. Article: Pfizer (PFE) Faces Expanded Vaccine Lawsuits On A Fair Value Narrative That Still Sees Upside

Pfizer Stock Down 1.9%

Shares of PFE opened at $24.52 on Friday. Pfizer Inc. has a 1 year low of $23.11 and a 1 year high of $28.75. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.25 and a quick ratio of 0.94. The stock has a 50 day simple moving average of $25.11 and a two-hundred day simple moving average of $26.16. The firm has a market cap of $139.78 billion, a P/E ratio of 18.72 and a beta of 0.35.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, topping the consensus estimate of $0.72 by $0.03. The firm had revenue of $14.45 billion for the quarter, compared to the consensus estimate of $13.84 billion. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The business’s revenue was up 5.4% compared to the same quarter last year. During the same period last year, the firm posted $0.92 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, analysts forecast that Pfizer Inc. will post 2.96 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 7.0%. The ex-dividend date is Friday, July 24th. Pfizer’s dividend payout ratio (DPR) is presently 131.30%.

Analysts Set New Price Targets

A number of equities analysts have commented on PFE shares. Wolfe Research reissued an “underperform” rating and issued a $26.00 price target on shares of Pfizer in a research note on Thursday, May 14th. CICC Research began coverage on shares of Pfizer in a research report on Thursday, April 16th. They set an “outperform” rating and a $33.00 price objective on the stock. JPMorgan Chase & Co. dropped their price objective on shares of Pfizer from $30.00 to $28.00 and set a “neutral” rating for the company in a report on Wednesday, July 8th. Royal Bank Of Canada upgraded shares of Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 target price for the company in a research report on Tuesday, June 9th. Finally, Morgan Stanley increased their target price on Pfizer from $27.00 to $28.00 and gave the company an “equal weight” rating in a research note on Friday, April 10th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $28.50.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.